Publications



  1. Daphne SC Lee, Sook-Yee Yoon, Lai Meng Looi, Peter Kang, In Nee Kang, Kavitta Sivanandan, Hany Ariffin, Meow Keong Thong, Kin Fah Chin, Nur Aishah Mohd Taib, Cheng Har Yip and Soo Hwang Teo. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Research (2012) 14:R66.
  2. Suhwan Chang, Rui-Hong Wang, Keiko Akagi, Kyung-Ae Kim, Betty K. Martin, Luca Cavallone, kConFab, Diana C. Haines, Mark Basik, Phuong Mai, Elizabeth Poggi, Claudine Isaacs, Lai M. Looi and Kein S. Mun, Mark H. Greene, Stephen W. Byers, Soo H. Teo, Chu-Xia Deng and Shyam K. Sharan.  Tumor Suppressor BRCA1 epigenetically controls oncogenic miRNA-155. Nature Medicine (2011) in press
  3. Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer. (2011) Feb 12. [Epub ahead of print
  4. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Laura Putignano A, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón Y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Gareth Evans D, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, John Kennedy M, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; CEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Catharina Dressler A, Hansen TV, Jønson L, Ejlertsen B, Bjork Barkardottir R, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Ewart Toland A, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; on behalf of CIMBA.  Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) in press
  5. A Mitra, EK. Bancroft, Y Barbachano, EC. Page, CS Foster, C Jameson, G. Mitchell, GJ Lindeman, A. Stapleton, G. Suthers, DG Evans, D Cruger, I Blanco, C Mercer, J Kirk, L Maehle, S Hodgson, L Walker, L Izatt, F Douglas, K Tucker, H Dorkins, V Clowes, A Male, A Donaldson, C Brewer, R Doherty, B Bulman, PJ Osther, M Salinas, D Eccles, K Axcrona, I Jobson, B Newcombe, C Cybulski, WS Rubinstein, S Buys, S Townshend, E Friedman, S Domchek, T Ramony Cajal, A. Spigelman, SH Teo, N Nicolai, N Aaronson, A Ardern-Jones, C Bangma, D Dearnaley, J Eyfjord, A Falconer, H Grönberg, F. Hamdy, O. Johannsson, V. Khoo, Z. Kote-Jarai, H. Lilja, J. Lubinski,  J. Melia, C. Moynihan, S. Peock, G. Rennert, F. Schröder, P. Sibley, M. Suri, P. Wilson, Y. J. Bignon, S. Strom, M. Tischkowitz, A. Liljegren, D. Ilencikova, A. Abele, K. Kyriacou, C. van Asperen, L. Kiemeney, Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. The IMPACT Study Collaborators, D. F. Easton and R Eeles BJU Int. (2011) 107(1):28-39
  6. Kang P, S Mariapun, Phuah SY, LS Lim, JJ Liu, Yoon SY, Thong MK, NA Mohd Taib, Yip CH and Teo SH. Large genomic rearrangements in BRCA1 and BRCA2 in Malaysian breast cancer patients. Breast Cancer Res Treat (2010) 124(2):579.
  7. Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH. Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country. World J Surg. (2009) 33: 2077 – 81.
  8. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. (2009) 10(3):395-8.
  9. E Thirthagiri, Cheong LS, CH Yip and SH Teo. CHEK2 1100delC does not contribute significantly to breast cancer risk in Malaysia's multi-ethnic population. Familial Cancer (2009) 8(4): 355-8.
  10. E Thirthagiri, SY Lee, P Kang, D Lee, GT Toh, SA Selamat, SY Yoon, NATaib, MK Thong, CH Yip, and SH Teo. Evaluation of BRCA1 and BRCA2 mutations and risk prediction models in a typical Asian country (Malaysia) with relatively low incidence of breast cancer. Breast Cancer Research (2008) 10 R59.
  11. GT Toh, P Kang, SS Lee, DS Lee, SY Lee, SA Selamat, NA Taib, SY Yoon, CH Yip and SH Teo. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PlosOne (2008)3(4) e2024.